Caribou Biosciences (NASDAQ: CRBU) revenue
Caribou Biosciences reported revenue of $11.2m for fiscal 2025, 11.7% more than in fiscal 2024 ($10.0m). Since fiscal 2020 its revenue has fallen by 9.7%, an average decline of 2.0% a year.
Caribou Biosciences's best year of the last 6 was fiscal 2023. The biggest drop was in fiscal 2024, −71.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $11.2m | +11.7% | −$148.3m | −1,329.4% |
| 2024 | $10.0m | −71.0% | −$166.6m | −1,667.2% |
| 2023 | $34.5m | +148.9% | −$116.1m | −336.6% |
| 2022 | $13.9m | +44.3% | −$106.4m | −768.2% |
| 2021 | $9.6m | −22.4% | −$67.0m | −697.8% |
| 2020 | $12.4m | — | −$36.1m | −292.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Caribou Biosciences revenue compared with its sector
By revenue for its latest fiscal year, Caribou Biosciences ranks 365th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Caribou Biosciences, 11.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 363rd | Tonix Pharmaceuticals | $13.1m | 29.8% |
| 364th | Prelude Therapeutics | $12.1m | 73.4% |
| 365th | Caribou Biosciences | $11.2m | 11.7% |
| 366th | Crescent Biopharma | $10.8m | — |
| 367th | Janux Therapeutics | $10.0m | −5.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Caribou Biosciences
- How much revenue did Caribou Biosciences make in fiscal 2025?
- Caribou Biosciences reported revenue of $11.2m for fiscal 2025, compared with $10.0m in fiscal 2024.
- How much has the revenue of Caribou Biosciences fallen?
- Between fiscal 2020 and fiscal 2025 it went from $12.4m to $11.2m: 9.7% less, an average decline of 2.0% a year.
- What was the best year for revenue at Caribou Biosciences?
- Of its last 6 fiscal years, fiscal 2023, with $34.5m.
- Where does Caribou Biosciences rank in its sector by revenue?
- It ranks 365th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Caribou Biosciences come from?
- From the annual report (Form 10-K) that Caribou Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Caribou Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Caribou Biosciences: the Caribou Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.